Atlas Trials

An Efficacy and Safety of CNTO 1959 (Guselkumab) in Participants With Moderate to Severe Plaque-type Psoriasis

Clinical trial NCT02325219 · COMPLETED

Trial details

NCT number
NCT02325219
Sponsor
Janssen Pharmaceutical K.K.
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Psoriasis
Start date
2014-12-19
Primary completion
2016-03-02
Enrollment
192

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.